Statement from Canada’s Pharmaceutical Industry Regarding House of Commons Motion on National Drug Strategy

OTTAWA and TORONTO, March 16, 2012 – The following is a joint statement by Russell Williams, President of Canada’s Research-Based Pharmaceutical Companies (Rx&D), and Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding the Motion passed by the House of Commons on a National Drug Strategy:

Canada’s pharmaceutical industry looks forward to working with the federal government, provincial and territorial governments, and our partners in the health-care sector to develop a nationwide strategy to anticipate, identify and manage shortages of prescription medications.

Despite the efforts of all parties in the pharmaceutical supply chain, shortages of prescription medicines can and do occur in Canada and other countries. These shortages may have an impact on patients and health-care providers and each incidence of a prescription drug shortage is of serious concern.

Earlier this week, CGPA and Rx&D announced our commitment and financial support to address both immediate and longer-term requirements to ensure that Canadians have the pharmaceutical treatments available when they need them. The plan will:

  • Permit inventory tracking available publicly on one bilingual website
  • Develop a system to report anticipated shortages
  • Recommend solutions when medications are not available

Both Rx&D and CGPA have committed to working closely with governments to implement these tracking, predictive and solution mechanisms on an urgent basis.

For further information please contact:

Jeff Connell
Vice President, Corporate Affairs
(416) 223-2333
Shannon MacDonald
Vice President, Public Affairs & Partnerships
(613) 236-0455